Current Clinical Trials

Research and clinical trials information at the Cancer Institute

For more information call our Clinical Trials Office at 865-305-9773.

The University of Tennessee Medical Center is the only SWOG (formerly Southwest Oncology Group) and NRG (National Surgical Aduvant Breast Bowel gynecological and Radiological) site member in the Knoxville area.



NRG  BR003 A Phase 3 trial for Triple Negative Breast Cancer comparing Doxorubicin plus cyclophosphamide followed by weekly Paclitaxel with or without Carboplatin.

Merck Keynote 355-00 A Phase 3 trial of Pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic Triple Negative Breast Cancer. 

Gastrointestinal: Colon, Rectum, Stomach, Hepatocellular

SWOG S0820 A placebo controlled trial of Eflornithine and Sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0 – III colon or rectal cancer.

SILLAJEN  Jx594-HEP024 A Phase 3 placebo controlled trial comparing Pexa-Vec ( vaccinia GM CSF / thymidine kinase-deactivated virus) followed by Sorafenib versus Sorafenib in patients with advanced hepatocellular carcinoma.


ECOG 2810 A Phase 3 trial using Pazopanib versus placebo in patients with metastatic renal cell carcinoma.

MERCK MK-3475-361 A randomized, double blind, Phase 2 study of Pembrolizumab with or without Platinum based combination chemotherapy vs. chemotherapy in subjects with advanced metastatic Urothelial cancer.

SWOG S1216 A Phase 3 trial comparing Androgen deprication therapy plus TAK-700 with Androgen deprication therapy + Bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer.


ALLIANCE A071102 A Phase 2/3 trial of Veliparib or Placebo in combination with adjuvant Temozolomide in newly diagnosed Glioblastoma with MGMT promoter Hypermethylation.

IMMUNOCELLULAR ICT-107-301 A Phase 3 trial of immunotherapy in newly diagnosed Glioblastoma. This is a placebo controlled study of Investigational product, ICT-107, in combination of Temozolomide following resection and concomitant Temozolomide chemoradiotherapy.


ASTRAZENECA D8488C00001 A Phase 2b trial of Cediranib and Olaparib in women with recurrent, primary, platinum resistant epithelial ovarian cancer.

EpicentRx A phase 2 study of RRx-001 in platinum refractory/resistant ovarian cancer prior to re-administration of platinum based doublet regimens.

GOG 0225 A study to determine if diet and physical activity modulate ovarian fallopian tube and primary peritoneal cancer progression – free survival

GOG 0238 A trial of pelvic irradiation with or without concurrent weekly Cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus.

GOG-0286B A randomized, phase 2/3 study of Paclitaxel/Carboplatin/Metformin versus Paclitaxel/Carboplatin/Placebo as initial therapy for measurable stage III or IVa, stage IVb, or recurrent endometrial cancer. 

MORPHOTEK MORab-003-011  A Phase 2 trial of Farletuzumab (MORab-003) in combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin in patients with Low CA 125, platinum sensitive recurrent ovarian cancer. 

Head and Neck

EpicentRx A phase 2 study of RRx-001 in platinum refractory/resistant ovarian cancer prior to re-administration of platinum based doublet regimens.

GALERA GT-201 A Phase 2  trial of the effects of  investigational product, GC4419, on the incidence and duration of severe oral mucositis in patients receiving post-operative or definitive therapy with single agent Cisplatin plus IMRT for locally advanced, non-metastatic squamous cell carcinoma of the oral cavity or oropharynx. 


CURIS CUDC-907-201 A Phase 2 trial of investigational product CUDC-907 with or without Rituximab in patients with relapsed/refractory diffuse large B-cell Lymphoma.

NCI 9177 A Phase II trial of dose adjusted EPOCH with or without Rituximab in adults with untreated Burkitt Lymphoma, C-Myc positive diffuse large B cell lymphoma and Plasmablastic Lymphoma.

PFIZER B3281066 A Phase 3 trial of investigational product, PF – 052800586, versus Rituximab for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma.

Multiple Myeloma

ECOG E3A06 A Phase 3 trial of Lenalidomide versus observation alone in patients with asymptomatic high risk smoldering multiple myeloma.


AMGEN 20070782 A trial to determine the efficacy in the use of Darbepoetin Alfa administered once every 3 weeks to treat Anemia in patients with Non-Small Lung Cancer.

CALGB 140503 A trial comparing Lobectomy versus Sublobar resection for small peripheral Non-Small Cell Lung Cancer.

EpicentRx A phase 2 study of RRx-001 in platinum refractory/resistant ovarian cancer prior to re-administration of platinum based doublet regimens.

G1 Therapeutics G1T28-02 A phase 1b/2a, placebo-controlled study to evaluate the effectiveness of G1T28 (investigational product) on reducing chemotherapy induced myleosuppression in patients with extensive stage small cell lung cancer receiving Etoposide and Carboplatin.

G1 Therapeutics G1T28-03 A phase 1b-2a safety and pharmacokinetic study of G1T28 in patients with previously treated extensive stage small cell lung cancer receiving Topotecan chemotherapy. 

LILY 14Y-MC-JFCP A Phase 2 trial of nab-Paclitaxel and Carboplatin chemotherapy plus Necitumumab in the first line treatment of patients with stage IV Squamous Non-Small Cell Lung Cancer.  


AMGEN MASTERKEY A Phase 3 trial of Talimogene (T-Vec) in combination of Pembrolizumab for treatment of unresectable, Stage IIIB to IVN1c melanoma.

NEWLINK NLG0304 A Phase 2b trial of Ipilmumab with or without HyperAcute Melanoma Immunotherapy for stage IV Melanoma patients.


BOSTON BIOMEDICAL BB1608-118 A Phase 1b trial of investigational product, BB1608 cancer stem cell therapy, in combination with Gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic adenocarcinoma.